Precision BioSciences, Inc. - DTIL STOCK NEWS

Precision BioSciences (Nasdaq: DTIL) announced it will present preclinical data on PBGENE-HBV, a program aimed at potentially eliminating hepatitis B virus (HBV). The oral presentation is scheduled for April 26, 2023, during the Global Hepatitis Summit in Paris, France. This program targets viral covalently closed circular DNA (cccDNA) for in vivo editing. The Chief Research Officer, Jeff Smith, emphasized the importance of specificity in gene editing to prevent off-target effects. Preclinical findings reveal that ARCUS nucleases achieve high on-target editing rates and reduce both intracellular cccDNA and hepatitis B surface antigen (HBsAg), without causing detectable translocations in human liver cells. This innovative approach supports the development of PBGENE-HBV as a potential cure for chronic HBV infections.

Precision BioSciences (DTIL) announced the selection of a late-breaking abstract featuring preclinical data from its PBGENE-DMD program for treating Duchenne Muscular Dystrophy (DMD). This presentation will take place at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA, from May 16-20, 2023. The PBGENE-DMD program utilizes ARCUS nucleases to excise a significant mutation area from the dystrophin gene, aiming to create a functional variant of the dystrophin protein. The oral presentation is scheduled for May 19, 2023, during the Late-breaking Abstracts 2 session, and public access to the abstract begins May 2, 2023. Precision BioSciences focuses on improving life through its novel gene editing platform, ARCUS, which is protected by a robust patent portfolio.

Precision BioSciences (NASDAQ: DTIL) has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application No. 16/606,856, concerning engineered meganucleases targeting the PCSK9 gene. This acknowledgment strengthens its intellectual property, allowing for gene editing to tackle cardiovascular diseases like familial hypercholesterolemia and offering potential for therapeutic gene insertion. The international applications in Europe, Australia, Mexico, Japan, and Israel are also progressing, with standard patent expiration dates set for October 2038 and August 2040 in the U.S. CEO Michael Amoroso highlights the safety and efficiency of ARCUS nucleases, which have diverse applications in gene editing, including ongoing programs with partners like Novartis and Lilly. In 2023, Precision plans to present new preclinical data and expects collaboration to file a CTA/IND for PCSK9 nuclease-related therapies.